Document Detail


Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
MedLine Citation:
PMID:  19153116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy. No standard schedule of irinotecan has been established in this situation. PATIENTS AND METHODS: Metastatic colorectal cancer patients included in the OPTIMOX1 phase III study received first-line oxaliplatin-based chemotherapy (FOLFOX). No second line was defined in the protocol, but data concerning second line were prospectively registered. Inclusion criterion was patients receiving an irinotecan-based second-line chemotherapy. Second-line progression-free survival (PFS) and tumor response were evaluated according to type of irinotecan-based regimen administered. RESULTS: A total of 342 patients received irinotecan-based chemotherapy as second-line chemotherapy: FOLFIRI-3 [n = 109, irinotecan 100 mg/m(2) days 1 and 3 combined with leucovorin (LV) 400 mg/m(2) day 1 and 46-h continuous 5-fluorouracil (5-FU) 2000 mg/m(2)], FOLFIRI-1 (n = 112, irinotecan 180 mg/m(2) day 1 combined with LV 400 mg/m(2) day 1, 5-FU bolus 400 mg/m(2) and 46-h continuous 5-FU 2400 mg/m(2)) and other various irinotecan-based regimens (n = 121). Median second-line PFS was 3.0 months (FOLFIRI-3: 3.7 months; FOLFIRI-1: 3.0 months; other regimens: 2.3 months). In multivariate analysis, FOLFIRI-3 regimen (relative risk 0.43, 95% confidence interval 0.28-0.68, P = 0.0003) and lactate deshydrogenase level at inclusion (P = 0.0006) in OPTIMOX1 were associated with a longer second-line PFS. CONCLUSION: In unselected patients pretreated with oxaliplatin, PFS in second line appeared to be improved by FOLFIRI-3 regimen.
Authors:
F-C Bidard; C Tournigand; T André; M Mabro; A Figer; A Cervantes; G Lledo; L Bengrine-Lefevre; F Maindrault-Goebel; C Louvet; A de Gramont
Related Documents :
12657236 - A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel...
17559146 - Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (irox) : intergrou...
24238126 - Laparoscopic versus open gastrectomy for gastric cancer: long-term oncologic results.
18613376 - A phase i trial of cpt-11 and s-1 combination chemotherapy in patients with metastatic ...
2889756 - Lymphomatoid papulosis. a follow-up study of 30 patients.
21464406 - Randomized, placebo-controlled, phase iii study of first-line oxaliplatin-based chemoth...
Publication Detail:
Type:  Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-01-19
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  20     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-25     Completed Date:  2009-07-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1042-7     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Hospital Saint Antoine, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  therapeutic use*
Camptothecin / administration & dosage,  analogs & derivatives
Colorectal Neoplasms / drug therapy*,  secondary
Female
Fluorouracil / administration & dosage
Humans
Leucovorin / administration & dosage
Male
Middle Aged
Organoplatinum Compounds / administration & dosage
Treatment Failure
Treatment Outcome
Chemical
Reg. No./Substance:
0/Folfox protocol; 0/Organoplatinum Compounds; 100286-90-6/irinotecan; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 63121-00-6/oxaliplatin; 7689-03-4/Camptothecin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients...
Next Document:  High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor...